Thailand BOI Okays Biotech Projects Worth 2.4 Bln Baht in Total Investment
- Futures firm after tax hike proposal, business activity data eyed
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Bitcoin sinks below $50,000 as cryptos stumble over Biden tax plans
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
- Euro regains poise as data points to stronger recovery
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
BANGKOK, April 5, 2021 /PRNewswire/ -- The Thailand Board of Investment (BOI) said today it has recently approved new projects in the field of advanced biotechnology, worth a combined 2.4 billion baht (around USD78 million) in investment, reflecting the increased interest of local and foreign investors in the country's biotech sector.
"These new and exciting projects reflect investors' continued interest in Thailand biotech capability," Ms. Duangjai Asawachintachit, Secretary General of the BOI. "Adding to our strong agricultural base and biodiversity, Thailand has now also a very strong pool of researchers that allow us to move into advanced technology."
Thai Kyowa Biotechnologies Co., Ltd., a producer of amino acids for pharmaceuticals affiliated to Japan's Kirin Holdings, received approval for an advanced biotech project to produce Human Milk Oligosaccharide (HMO), a prebiotic and key ingredient in milk powder for infants and adults, helping to build immunity. The fully Japanese-owned company, located in Thailand's eastern province of Rayong, expects HMO production to start in 2022, mainly for exports.
Genepeutic Bio Co., Ltd., a company established by doctors from the Ramathibodi hospital in Bangkok, and local investors, received approval for a project to develop and produce an innovative treatment for patients with Acute Lymphoblastic Leukemia (ALL). The company, based in the Thailand Science Park, close to the country's capital, was setup to develop CAR T Cell advanced therapy medicinal products (ATMP).
Fruita Biomed Co., Ltd., a company related to Thailand's Fruita Natural Co., Ltd., a food and beverage producer and exporter, received approval for a project to produce PHA (Polyhydroxyalkanoate) bioplastic and PHA bioplastic compound developed from organic waste. The company will use the PHA bioplastic to make a wide range of packaging products for food and medical supply as well.
Baiya Phytopharm, Co, Ltd., a Thai startup linked to the CU Innovation Hub, the incubator setup by Bangkok's well known Chulalongkorn University, received approval for a project to develop and produce biopharmaceuticals, including plant-based vaccines and therapeutic proteins, using molecular pharming technology.
The biotechnology sector is part of the so-called BCG model (Bio, Circular and Green economy) which the Thai government has set as a priority to lead the post-Covid 19 recovery.
For more information, please contact: Thailand Board of InvestmentTel. +66 (0) 2553 8111Website: www.boi.go.thYouTube: Think Asia, Invest Thailand
View original content to download multimedia:http://www.prnewswire.com/news-releases/thailand-boi-okays-biotech-projects-worth-2-4-bln-baht-in-total-investment-301261937.html
SOURCE Thailand Board of Investment (BOI)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Def Leppard To Release Limited Edition Box Set 'Def Leppard - Volume Three' On June 11, 2021
- Chicago Apprentice Network Surpasses 1,000 New Apprenticeships Since 2017 Launch
- INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800